Information Provided By: 
Fly News Breaks for December 8, 2015
GWPH
Dec 8, 2015 | 05:53 EDT
Piper Jaffray analyst Joshua Schimmer says Epidiolex is well positioned after GW Pharmaceuticals investigators presented the full data from the expanded access program in late breaking posters at American Epilepsy Society annual meeting which also covered Epidiolex in epileptic spasms and tuberous sclerosis complex. The believe the totality of the data "suggests a highly active compound, and bodes well for the Phase 3 program and beyond," Schimmer tells investors in a research note. He reiterates an Overweight rating on GW with a $147 price target.
News For GWPH From the Last 2 Days
There are no results for your query GWPH
